- Home
- ANL vs FORA Comparison
ANL vs FORA Comparison
Compare ANL & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- FORA
- Stock Information
- Founded
- ANL 2004
- FORA 2014
- Country
- ANL Cayman Islands
- FORA United States
- Employees
- ANL N/A
- FORA N/A
- Industry
- ANL
- FORA Computer Software: Prepackaged Software
- Sector
- ANL
- FORA Technology
- Exchange
- ANL Nasdaq
- FORA Nasdaq
- Market Cap
- ANL 61.8M
- FORA 60.2M
- IPO Year
- ANL 2023
- FORA N/A
- Fundamental
- Price
- ANL $1.79
- FORA $2.21
- Analyst Decision
- ANL Hold
- FORA Strong Buy
- Analyst Count
- ANL 1
- FORA 1
- Target Price
- ANL N/A
- FORA $5.00
- AVG Volume (30 Days)
- ANL 9.3K
- FORA 74.8K
- Earning Date
- ANL 09-26-2025
- FORA 11-12-2025
- Dividend Yield
- ANL N/A
- FORA N/A
- EPS Growth
- ANL N/A
- FORA N/A
- EPS
- ANL N/A
- FORA N/A
- Revenue
- ANL N/A
- FORA $25,031,040.00
- Revenue This Year
- ANL N/A
- FORA $47.82
- Revenue Next Year
- ANL N/A
- FORA $10.11
- P/E Ratio
- ANL N/A
- FORA N/A
- Revenue Growth
- ANL N/A
- FORA 18.59
- 52 Week Low
- ANL $1.10
- FORA $1.64
- 52 Week High
- ANL $3.89
- FORA $4.03
- Technical
- Relative Strength Index (RSI)
- ANL 60.57
- FORA 57.72
- Support Level
- ANL $1.65
- FORA $2.20
- Resistance Level
- ANL $1.88
- FORA $2.39
- Average True Range (ATR)
- ANL 0.10
- FORA 0.13
- MACD
- ANL 0.00
- FORA 0.02
- Stochastic Oscillator
- ANL 58.02
- FORA 64.71
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.